Patricia Inácio, PhD, science writer —

Patricia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. She also served as a PhD student research assistant in the Department of Microbiology & Immunology, Columbia University, New York, for which she was awarded a Luso-American Development Foundation (FLAD) fellowship.

Articles by Patricia Inácio

Secondary Insurance Coverage Boosts Adherence to Treatment with Ofev, Esbriet, Study Finds

Although patients with idiopathic pulmonary fibrosis (IPF) who take Ofev (nintedanib) or Esbriet (pirfenidone) have similar clinical outcomes, adherence to treatment is higher among those who have secondary insurance coverage, especially from charitable organizations, a study finds. The study, “Retrospective Analysis of Medication Utilization and Clinical Outcomes in…

Ofev Affects Cell Cycle Genes in IPF Fibroblasts, Study Finds

Ofev (nintedanib) may exert its therapeutic benefits by halting the activity of genes that promote proliferation of fibroblasts in idiopathic pulmonary fibrosis (IPF), a next-generation sequencing study suggests. The study “Gene Expression Changes Associated with Nintedanib Treatment in Idiopathic Pulmonary Fibrosis Fibroblasts: A Next-Generation Sequencing and Bioinformatics…